Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-16, Stock:LLY, The news for the past five days is as follows:
2018-11-09: NEWS1: Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update.NEWS2: Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update.NEWS3: Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag.NEWS4: Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag.NEWS5: Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update.NEWS6: Keryx&apos;s (KERX) Loss Narrower Than Expected in Q3, Sales Lag.NEWS7: Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss.NEWS8: Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS10: Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug.
2018-11-12: NEWS1: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS2: IBD Stock Of The Day Nears Buy Point As It Outperforms Big Pharma Rivals.NEWS3: 5 Stocks to Sell After the Midterm Election.NEWS4: AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark.NEWS5: AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark.
2018-11-13: NEWS1: More and More Hedge Funds Are Selling Eli Lilly and Company (LLY).NEWS2: Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates.NEWS3: Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates.NEWS4: Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates.NEWS5: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for November 14, 2018.NEWS6: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for November 14, 2018.NEWS7: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS8: Walmart, Home Depot adopt health insurer tactic in drug copay battle.NEWS9: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS10: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.
2018-11-14: NEWS1: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS2: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS3: Migraine-Focused Biotech Has A Headache On Quarterly Losses.NEWS4: AbbVie&apos;s HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS5: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS6: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS7: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS8: Shire's Filing Accepted by FDA for Gattex's Label Expansion.NEWS9: Shire's Filing Accepted by FDA for Gattex's Label Expansion.NEWS10: Shire&apos;s Filing Accepted by FDA for Gattex&apos;s Label Expansion.NEWS11: Eli Lilly announces progress on new headache medications.NEWS12: Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache.
2018-11-15: NEWS1: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS2: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS3: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS4: Exploring Clovis Oncology’s Operational Performance.NEWS5: Understanding Clovis Oncology’s Gross Margin Trend.NEWS6: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS7: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS8: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS9: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.NEWS10: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.NEWS11: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.

Answer: Rise